- Home
- ACOG vs ACHV Comparison
ACOG vs ACHV Comparison
Compare ACOG & ACHV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACOG
- ACHV
- Stock Information
- Founded
- ACOG 2000
- ACHV N/A
- Country
- ACOG Canada
- ACHV Canada
- Employees
- ACOG N/A
- ACHV N/A
- Industry
- ACOG
- ACHV Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- ACOG
- ACHV Health Care
- Exchange
- ACOG Nasdaq
- ACHV Nasdaq
- Market Cap
- ACOG 80.3M
- ACHV 72.5M
- IPO Year
- ACOG N/A
- ACHV N/A
- Fundamental
- Price
- ACOG $9.74
- ACHV $3.90
- Analyst Decision
- ACOG Strong Buy
- ACHV Strong Buy
- Analyst Count
- ACOG 1
- ACHV 3
- Target Price
- ACOG $20.00
- ACHV $14.33
- AVG Volume (30 Days)
- ACOG 196.9K
- ACHV 247.2K
- Earning Date
- ACOG 05-15-2025
- ACHV 05-13-2025
- Dividend Yield
- ACOG N/A
- ACHV N/A
- EPS Growth
- ACOG N/A
- ACHV N/A
- EPS
- ACOG N/A
- ACHV N/A
- Revenue
- ACOG $2,928,654.00
- ACHV N/A
- Revenue This Year
- ACOG N/A
- ACHV N/A
- Revenue Next Year
- ACOG N/A
- ACHV N/A
- P/E Ratio
- ACOG N/A
- ACHV N/A
- Revenue Growth
- ACOG N/A
- ACHV N/A
- 52 Week Low
- ACOG $3.75
- ACHV $1.84
- 52 Week High
- ACOG $11.40
- ACHV $5.58
- Technical
- Relative Strength Index (RSI)
- ACOG N/A
- ACHV 74.55
- Support Level
- ACOG N/A
- ACHV $2.89
- Resistance Level
- ACOG N/A
- ACHV $3.32
- Average True Range (ATR)
- ACOG 0.00
- ACHV 0.27
- MACD
- ACOG 0.00
- ACHV 0.09
- Stochastic Oscillator
- ACOG 0.00
- ACHV 98.69
About ACOG Alpha Cognition Inc. Common Stock
Alpha Cognition Inc is a biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer's disease, for which there are limited or no treatment options. The Company's current focus is on the commercial manufacturing and sales of ZUNVEYL oral tablet formulation. The Company's commercial development program for ZUNVEYL is primarily focused on building a long-term care commercial team that can focus on providing key points of differentiation, exploiting key issues with existing Acetylcholinesterase inhibitors treatments, and seeking potential licensing partners for other additional indications and new formulations.
About ACHV Achieve Life Sciences Inc.
Achieve Life Sciences Inc is a specialty pharmaceutical company committed to advancing cytisinicline as a widely available treatment option to help people battling nicotine addiction. It is an established smoking cessation treatment that has been approved and marketed in Central and Eastern Europe. Achieve's focus is to address the smoking health epidemic through the development and commercialization of cytisinicline. It has one operating segment, dedicated to the development and commercialization of cytisinicline for niceon.